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ABSTRACT
Introduction: The effect of exenatide in weight
loss has been reported. Presented here is a case
of a morbidly obese patient with type 2 diabetes
using exenatide who dramatically lost her body
weight in a year and experienced improved
glycemic control.
Case report: Exenatide therapy was initiated
for a 59-year-old morbidly obese Japanese
woman with type 2 diabetes. To examine
the effects of the exenatide treatment,
continuous glucose monitoring was
performed, and blood was drawn at 0, 30,
60, 120, and 180 min after breakfast to
measure insulin, glucagon, glucagon-like
peptide-1 (GLP-1), and glucose-dependent
insulinotropic peptide (GIP) levels. After
1 year of exenatide therapy, the patient lost
37.5 kg, her glycemic control improved, and
her insulin sensitivity recovered. The patient’s
levels of insulin, glucagon, active GLP-1, and
total GIP also decreased after 1 year of
exenatide treatment.
Conclusion: The exenatide treatment was
effective for reducing body weight and
improving glycemic control. After 1 year of
exenatide treatment, decreased glucagon,
active GLP-1, and total GIP levels were
observed following a meal, suggesting that
exenatide might affect these hormonal
reactions.
Keywords: Exenatide; Glucagon; Glucose-
dependent insulinotropic peptide; Glucagon-
like peptide-1; Insulin sensitivity; Type 2
diabetes mellitus
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INTRODUCTION
Overweight and obesity are defined as abnormal
or excessive fat accumulation that may impair
health. The World Health Organization (WHO)
estimates that at least 2.8 million adults die each
year as a result of being overweight or obese and
that 44% of the diabetes burden, 23% of the
ischemic heart disease burden, and 7–41% of the
burden associated with certain cancers are
attributable to overweight and obesity [1].
Links between obesity and diabetes have
been firmly established [2–4]. In obesity,
visceral fat secretes adipocytokines such as
tumor necrosis factor-a (TNF-a) [5] and resistin
[6], resulting in insulin resistance, which then
progresses to impaired insulin secretion. Weight
reduction can attenuate the abnormal
adipocytokine secretion and may improve
insulin resistance and glucose metabolism [7].
Therefore, weight loss can be used as a
therapeutic treatment for patients with
obesity-induced diabetes; however, if the
desired weight loss is not achievable,
medication for diabetes management is
necessary in addition to weight management.
Gut peptides, including glucagon-like
peptide-1 (GLP-1) and glucose-dependent
insulinotropic polypeptide (GIP), are secreted
in a nutrient-dependent manner and stimulate
glucose-dependent insulin secretion [8, 9].
Exenatide, a GLP-1 analog, is a new class of
antidiabetic drug that potentiates glucose-
dependent insulin secretion, lowers serum
glucagon levels, slows gastric emptying, and
may promote weight loss by increasing satiety
[10–13]. The effect of exenatide in weight loss
has been reported, with considerable variation
in the amount of weight that is lost [14–23].
This case report presents a case of a morbidly
obese patient with type 2 diabetes using
exenatide who successfully lost 37.5 kg of
body weight in a year and experienced
improved glycemic control. To assess the
efficacy of this drug, we also report hormonal
changes in insulin, glucagon, GLP-1, and GIP
levels before and after the exenatide treatment.
CASE REPORT
History of Obesity and Diabetes
A 59-year-old Japanese woman began
experiencing weight gain at the age of 38 years
due to overeating in response to mental stress.
When she was 48 years old, she retired from
work because of a disc herniation; as a result,
she spent most of her time at home, decreased
her physical activity, and gained additional
weight. At the age of 49 years, her body
weight reached 153 kg [height 156.2 cm, body
mass index (BMI) 62.7 kg/m2]. Hormonal
examinations revealed that she was unlikely to
have endocrinological diseases such as
Cushing’s disease or hypothyroidism. Her
HbA1c level was 8.8% at this time, and she
was admitted to the hospital for obesity and
glucose management. After 15 weeks in hospital
with a dietary intake of 1,200 kcal per day, her
weight was successfully reduced to 131.2 kg
(BMI 53.9 kg/m2) and her HbA1c level also
decreased to 6.5%. However, after discharge,
she gradually regained weight to 163.0 kg (BMI
66.8 kg/m2) and her HbA1c level increased to
9.3%. Thereafter, she repeatedly gained and lost
weight and required ongoing weight
management support. In 2010, at the age of
55 years and a weight of 144.1 kg (BMI
59.1 kg/m2), she required a total dosage of 36
units of insulin by injection, and her glycemic
control was poor (HbA1c 10.5%). However, as
she gradually reduced her weight again to
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121 kg (BMI 49.6 kg/m2), her total dosage of
insulin also decreased to 28 units. Finally, at a
body weight of 114 kg (BMI 46.7 kg/m2), she
could maintain an HbA1c level of 6.6% without
the use of medication, including insulin
injections.
Previous weight management strategies
included the use of the anti-obesity drug
mazindol, a very low calorie diet (800 kcal/
day), and counseling by a psychotherapist.
Exercise therapy was restricted to the upper
part of the body because of knee pain resulting
from weight-induced osteoarthritis. While the
aforementioned strategies were effective during
a hospital admission, they did not result in
long-term weight loss after discharge. Gastric
surgery (e.g., sleeve gastrectomy) was also
considered, but it was not performed due to
her inability to cover the medical expense and
the presence of renal dysfunction [eGFR,
21.8 mL/(min1.73 m2)].
Administration of Exenatide
Following the patient’s weight reduction in
March 2011 to 112.1 kg (BMI 45.9 kg/m2), she
regained her weight and more to reach 133.8 kg
(BMI 54.8 kg/m2) in August 2012, and her HbA1c
level was 8.2%. Therefore, exenatide therapy was
commenced with 5 lg injected twice a day
within the 60 min before the morning and
evening meals. The goals of this therapy were
glycemic control and weight loss. In August
2013, following 1 year of exenatide therapy, her
weight was 96.3 kg (BMI 39.5 kg/m2).
Glucose metabolism was assessed at 3
occasions (March 2011, August 2012, and
August 2013) with a continuous glucose
monitoring system (CGMS) (CGMS-GOLDTM;
Medtronic MiniMed, Northridge, CA, USA), and
measurements of serum insulin and plasma
glucagon were conducted using blood samples
that were drawn at 5 time points (0, 30, 60, 120,
and 180 min) after breakfast following a 14-h
overnight fast.
In addition, to assess the changes in incretin
markers before the exenatide treatment,
baseline active GLP-1 and total GIP levels were
also measured at the 5 time points after
breakfast in August 2012. To assess the effect
of the exenatide treatment over 1 year, a
washout period (5 days without exenatide) was
conducted prior to the assessment in August
2013, and active GLP-1 and total GIP levels were
measured at the same 5 time points after
breakfast. Blood samples for the determination
of active GLP-1 and total GIP levels were
collected into BDTM P800 tubes (Becton-
Dickinson, Franklin Lakes, NJ, USA)
containing spray-dried K2EDTA anticoagulant
and a proprietary cocktail of protease, esterase,
and dipeptidyl peptidase 4 (DPP-4) inhibitors.
The area under the curve (AUC) values for
continuous glucose monitoring (CGM)
measured glucose, insulin, glucagon, active
GLP-1 and total GIP levels, after meal
ingestion, were calculated using the
trapezoidal rule.
For all occasions, total caloric intake was
maintained at 1,600 kcal per day (breakfast
365–410 kcal). To assess the minimum amount
of energy required by the patient, her resting
metabolic rate (RMR) was measured using a
FitMate metabolic system (Cosmed, Rome,
Italy).
Finally, to evaluate the levels of insulin
resistance and insulin secretion in this patient,
the homeostasis model assessment of insulin
resistance (HOMA-IR) and the homeostasis
model assessment of b cell function (HOMA-b)
were done [24, 25]. In addition, the quantitative
insulin-sensitivity check index (QUICKI) was
calculated using the standard formula: 1/[log
(glucose) ? log (insulin)] [26].
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All procedures followed were in accordance
with the ethical standards of the responsible
committee on human experimentation
(institutional and national) and with the
Helsinki Declaration of 1975, as revised in
2000 and 2008. Informed consent was
obtained from the patient for being included
in the study.
RESULTS
During the periods of exenatide administration,
the patient experienced mild gastrointestinal
symptoms such as nausea and appetite loss;
however, these adverse effects were not serious
enough to cease the exenatide therapy. Changes
in body weight, BMI, HbA1c levels, RMR,
HOMA-IR, HOMA-b, and QUICKI at the 3
measurement points (March 2011, August
2012, and August 2013) are shown in Table 1.
As weight was lost, the RMI and HOMA-IR
reduced while QUICKI values increased. The
value of HOMA-b decreased in August 2012
after the weight gain and did not change
following the weight loss in August 2013.
Figure 1 shows the fluctuations in glucose
levels measured by CGM. The
average ± standard deviation (SD) of the CGM
measurements for each of the three occasions
(March 2011, August 2012, and August 2013)
was 119.7 ± 7, 197 ± 16, and 117 ± 7 mg/dL,
respectively, reflecting the attenuation of
glucose fluctuations with weight loss.
Time-dependent changes in serum insulin,
plasma glucagon, active GLP-1, and total GIP
levels are shown in Fig. 2. The AUC values of
these hormones up to 3 h after the meal
ingestion are summarized in Table 2.
Compared to August 2012, the insulin levels
and insulin AUC values were lower at each
measurement in March 2011 and August 2013
(Fig. 2a). Glucagon levels and glucagon AUC
values at each measurement were lower in
August 2013 compared to those in March 2011
and August 2012 (Fig. 2b). The active GLP-1 and
total GIP levels decreased at all of the
measurement points in August 2013 compared
to those in August 2012 (Fig. 2c, d).
DISCUSSION
Although substantial lifestyle changes, such as
an increase in physical activity and dietary
modifications, are essential and effective for
obesity management; low compliance results in
a need for pharmacological or surgical
intervention in some cases. For the patient in
this report, dietary modifications, exercise, and
a pharmacological intervention were not
effective, and surgical intervention was not an
option. However, the use of exenatide
contributed to a 37.5 kg weight loss and
improved glycemic control in the patient. This
improvement in glycemic control was related to
both the weight loss and exenatide therapy;
Table 1 Anthropometric and glucose metabolism
parameters at 3 time points
Parameter 2011 Mar 2012 Auga 2013 Aug
Body weight (kg) 112.1 133.8 96.3
BMI (kg/m2) 45.9 54.8 39.5
HbA1c (%) 6.0 8.2 5.1
RMR (kcal/day) 1,732 2,331 1,618
HOMA-IR 1.08 4.89 1.29
HOMA-b (%) 95.4 55.7 57.2
QUICKI 0.201 0.082 0.195
BMI body mass index, RMR resting metabolic rate,
HOMA-IR homeostasis model assessment ratio, HOMA-b
homeostasis model assessment b cell function, QUICKI
quantitative insulin-sensitivity check index
a Exenatide treatment commenced (5 lg injected twice a
day within the 60 min before the morning and evening
meals) and continued until August 2013
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Fig. 1 The results of continuous glucose monitoring
(CGM) in a morbidly obese female patient with type 2
diabetes in March 2011 (a), August 2012 (b), and August
2013 (c). Exenatide treatment commenced (5 lg injected
twice a day within the 60 min before the morning and
evening meals) in August 2012 and continued until August
2013. Marks on the lines indicate a calibration of the CGM
system, and the marks at the bottom of the ﬁgures indicate
the three meals
Fig. 2 Time course of insulin (a), glucagon (b), active
glucagon-like peptide-1 (GLP-1) (c), and total glucose-
dependent insulinotropic polypeptide (GIP) (d) levels before
and after food intake in a morbidly obese female patient with
type 2 diabetes. The ﬁlled squares indicate results in March
2011, the ﬁlled triangles indicate the results in August 2012,
and the clear triangles indicate the results in August 2013.
Exenatide treatment commenced (5 lg injected twice a day
within the 60 min before the morning and evening meals) in
August 2012 and continued until August 2013
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however, the exenatide injections were ceased
for the 5 days before the assessment in Aug
2013. Therefore, weight loss is likely to be the
primary reason for the observed changes.
The fluctuations in the post-prandial insulin
levels displayed in the patient were related to
the changes in her weight; when her weight was
higher (133.8 kg), the insulin levels increased,
and when her weight was lower (112.1 and
96.3 kg), the insulin levels decreased. This
relationship indicated that the level of insulin
resistance decreased, and the hyperinsulinemia
was ameliorated.
Glucagon levels decreased after 1 year of
exenatide therapy, despite the decrease in
glucose levels. Although GLP-1 is a powerful
suppressor of glucagon secretion, a decrease in
glucose levels should result in increased
glucagon secretion. The balance of these
phenomena may lead to a decrease in
glucagon secretion. Secretion of GLP-1 is
generally impaired in obesity [27] resulting in
a reduction in the circulating GLP-1 levels in
obese patients [10, 28, 29]. Moreover, the GLP-1
response to oral stimulation has been negatively
correlated with BMI [27, 29], and weight loss is
associated with an increased GLP-1 response to
meal ingestion [28]. However, in this case
report, the patient’s GLP-1 levels were reduced
at all of the post-prandial measurements
following the exenatide treatment. This may
be due to the decreased glucose levels because
GLP-1 is secreted in a glucose-dependent
manner. In addition, the effect of exenatide
on gastric emptying or the inhibitory feedback
for GLP-1 secretion may explain the reduction
in GLP-1 levels [14, 30]. The post-prandial total
GIP levels were also decreased in the patient
following exenatide therapy. The potential
reason for this is unclear, but it might be
attributed to the reduction in glucose levels.
Measurements of active GIP in future studies
may provide more insight into this relationship.
Islet b cell failure in type 2 diabetes occurs
when the islets are unable to sustain b cell
compensation in the presence of insulin
resistance. Weight loss often improves islet b
cell function in association with reductions in
insulin resistance [31, 32]. However, the islet b
cell failure may be progressive and, therefore, not
recoverable, particularly after hyperglycemia is
established, which leads to poorly functioning,
de-differentiated b cells, and a loss of b cell mass
from apoptosis [33]. Preclinical studies provide
strong evidence that exenatide plays an
important role in the maintenance of b cell
mass and function by increasing the expression
of key b cell genes, stimulating islet cell
proliferation and neogenesis, and inhibiting
islet cell apoptosis [13]. However, human b cells
appear to be much less responsive to proliferative
agents such as GLP-1 compared to rodent b cells
[34], and b cell replication is substantially
diminished in older human subjects [35]. This
may explain the changes observed in the
HOMA-b values in the patient, which indicated
that the ability to secrete insulin was not









(103 9 mg/dL3 h)
23.4 34.9 21.4
Insulin (103 9 pmol/L3 h) 12.7 24.6 12.2
Glucagon (103 9 ng/L3 h) 18.2 15.5 13.0
GLP-1 (active) (102 9 pmol/L3 h) N/A 3.7 2.9
GIP (total) (103 9 pmol/L3 h) N/A 15.1 8.9
CGM continuous glucose monitoring, GIP glucose-
dependent insulinotropic polypeptide, GLP-1 glucagon-
like peptide-1, N/A not available
a Exenatide treatment commenced (5 lg injected twice a
day within the 60 min before the morning and evening
meals) and continued until August 2013
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recovered following exenatide treatment and
concurrent weight loss.
Peptide YY3–36 [36], leptin [37–40], resistin [6],
and ghrelin [41] are the hormones that modulate
appetite and affect food intake. The levels of
these hormones were not measured; however,
they may contribute to understanding the
extreme weight loss by exenatide in the patient.
A previous study [42] demonstrated that
1 year of exenatide treatment significantly
improved b cell function and decreased body
weight in the presence of similar improvements
in glycemic control, when compared with
insulin glargine treatment. However, after
cessation of the exenatide therapy, these
beneficial effects were not sustained,
suggesting that ongoing treatment is necessary
for exenatide to be effective. Similarly, in the
present study, the patient’s appetite recovered
after ceasing exenatide treatment, and she
regained 3 kg within the following 2 months.
The treatment with another type of GLP-1
receptor agonist, liraglutide, led to weight loss
in overweight or obese patients with or without
type 2 diabetes [43–47]. In addition, the current
phase 3, randomized, controlled trial
demonstrates the efficacy of liraglutide 3.0 mg
per day, combined with lifestyle modification,
in facilitating the maintenance of clinically
meaningful weight loss; thus, liraglutide holds
promise as an anti-obesity drug [48]. Moreover,
a once-weekly formulation of exenatide was
developed recently, and patients treated with
once-weekly exenatide showed better glycemic
control with sustained overall weight loss than
patients treated with insulin glargine [49, 50].
Therefore, these drugs can be an alternative
option for patients such as the one described in
this case report.
In conclusion, 1 year of exenatide treatment
was effective for reducing body weight and
improving glycemic control in a 59-year-old
morbidly obese woman with type 2 diabetes. At
the same time, her insulin sensitivity recovered
but the ability to secrete insulin did not recover.
After 1 year of exenatide treatment, decreased
glucagon, active GLP-1, and total GIP levels
were observed following a meal, suggesting that
exenatide might affect these hormonal
reactions.
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